After an FDA rejection of its spinocerebellar ataxia (SCA) therapy, Biohaven was forced to rethink its strategy—cutting R&D spend by 60% and channeling the spirit of a scrappy startup again as it ...
While the major equity indexes have experienced a choppy Q4, a number of groups within the health care sector have shown strong resilience. Pharmaceuticals and biotechs have generally outperformed the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
13d
There's a 'bearish-to-bullish' reversal happening in this mid-cap biotech stock, says Carter Worth
In the throes of a "bearish-to-bullish" reversal, the stock exhibits bullish price-volume correlation and impressive relative strength to the market and to other biotechnology stocks. We're buyers ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
About Sartorius Stedim Biotech S.A. Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The ...
About Cardiac Biotech Solutions Inc. Cardiac Biotech Solutions, Inc. engages in the provision of products and services in the ambulatory non-invasive cardiac monitoring space. The firm's FDA and CE ...
AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results